Clinilabs Selected for a Phase II Study of Major Depressive Disorder
Clinilabs, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced that they have been selected to conduct a Phase II clinical research study of an investigational medication in patients with Major Depressive Disorder.
The trial will examine the effects of an investigational medication in treatment resistant patients who are experiencing a current episode of depression. This is Clinilabs’ fifth study in this therapeutic area. Dr. Stephen Murray, Clinilabs’ Chief Medical Officer states: “Major Depressive Disorder is a debilitating disease that carries with it both emotional and physical symptoms. I am pleased to be involved in a clinical trial that is assessing a novel medication that may combat this condition.”
Enrollment for this study has begun. Referrals from physicians and other healthcare providers are welcomed. Individuals in the New York City Metro area who suffer from Major Depressive Disorder can contact our call center at 212-994-4567 to prequalify. Additional information may also be found by visiting www.clinilabs.com/mdd.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
